1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Peptic Ulcer Drugs Market
2.2. Global Peptic Ulcer Drugs Market, By Drug, 2023 (US$ Million)
2.3. Global Peptic Ulcer Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Peptic Ulcer Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Peptic Ulcer Drugs Market Vendors
3.2. Strategies Adopted by Peptic Ulcer Drugs Market Vendors
3.3. Key Industry Strategies
4. Peptic Ulcer Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Peptic Ulcer Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Drug
5.3.2. Proton Pump Inhibitors (PPIs)
5.3.3. H2 Receptor Antagonists
5.3.4. Gastric Mucosal Protective Drugs
5.3.5. Antacids
5.3.6. Prostaglandin Agonists


6. North America Peptic Ulcer Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.Peptic Ulcer Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Peptic Ulcer Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.Peptic Ulcer Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Peptic Ulcer Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.Peptic Ulcer Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)

9. Latin America Peptic Ulcer Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.Peptic Ulcer Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Peptic Ulcer Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.Peptic Ulcer Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Peptic Ulcer Drugs Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. AstraZeneca plc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Cadila Healthcare Ltd.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Daewoong Pharmaceuticals
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Eisai Co. Ltd.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. PharmaKing Co. Ltd.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Taiho Pharmaceutical (A Otsuka Holdings)
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Takeda Pharmaceutical
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Yuhan Corporation
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives